INTRODUCTION
hemoglobinopathies
HEMOGLOBINOPATHIES
Inhibitors of the mammalian target of rapamycin (mTOR) have been proposed by many studies to improve vaccine responses, especially in elderly. This was for instance reported to impact on the Flu vaccine efficacy.In this respect, Sirolimus (also known as rapamycin, a lipophilic macrolide isolated from a strain of Recently, Sirolimus has been considered in laboratory and clinical studies aimed to find novel protocols for the therapy of hemoglobinopathies (e.g. β‐Thalassemia and sickle‐cell disease).The results of the trial were obtained in 8 patients with βThe major end points of the NCT03877809 clinical trial were not aimed to explore changes in the functionality of memory T cells of Sirolimus‐treated patients.The objective of the present study was to analyse the activity of CD4